Belgium - Updated Guidance on Submissions re CTAs, Substantial Amendments, and End-of-trial Declaration

On 5 August 2021 the Belgium FAMHP updated the guidance on the submission of clinical trial applications.

This document is intended to update the guidance on the submission of clinical trial applications, substantial amendment notifications and end of trial declarations to the competent authority in Belgium (FAMHP).

Read the pdf 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /